It helps to have a friend. And for several pharma giants scrambling to cut R&D costs, those friends are venture capital firms that co-invest in startups whose new drugs and platform technologies appear attractive. In some cases, these pharma-venture “alliances” launch the startups, using the expertise of VC firm partners and company executives.
{iframe}http://www.genengnews.com/insight-and-intelligenceand153/12-industry-venture-fund-alliances-2014-edition/77900213/{/iframe}